CapsoVision, Inc: management transactions · United States · SEC (Form 4)

About CapsoVision, Inc

CapsoVision, Inc. is a U.S.-based medical technology company listed on the NASDAQ Capital Market under the ticker CV. Headquartered in Saratoga, California, United States, the company was founded in 2005 and has built its business around advanced imaging and AI-enabled solutions for gastrointestinal diagnostics. Its strategy is centered on capsule endoscopy, combining a wire-free device platform, cloud-based review workflows and internally developed software capabilities. The company’s lead product is CapsoCam Plus®, a panoramic 360-degree capsule endoscope designed to visualize the small bowel and help clinicians detect conditions such as obscure GI bleeding, anemia and Crohn’s disease. CapsoVision sells the product directly in the U.S. and through direct and indirect channels internationally. Beyond the commercial small-bowel franchise, the company is advancing CapsoCam Colon, a next-generation product intended to enable non-invasive colon visualization and polyp detection. It is also developing an AI-assisted reading module aimed at improving lesion detection sensitivity, shortening review times and enhancing polyp sizing capabilities. From a competitive standpoint, CapsoVision differentiates itself through a wire-free design, proprietary cloud architecture and a growing AI layer. That combination is meant to reduce the need for on-site servers or specialized infrastructure, simplify deployment across care settings and improve physician workflow. In practical terms, the company is targeting gastroenterology practices, hospitals and larger care networks, while also pursuing opportunities in pediatrics and broader screening use cases across the GI tract. Its positioning places it among innovative niche players in capsule endoscopy rather than broad-based medtech platforms. Recent company updates indicate that CapsoVision is still in a build-and-scale phase, but with meaningful commercial traction. Management reported that CapsoCam Plus had been used in over 161,000 patients as of December 31, 2025. For full-year 2025, revenue increased and the company submitted a 510(k) application to the FDA for its in-house AI-assisted module. In March 2026, CapsoVision also announced the closing of a $14 million private placement, underscoring continued capital needs as it funds product development, regulatory work and commercial expansion. For investors following U.S. listed healthcare names, CV offers exposure to a specialized medtech story on the NASDAQ in the United States, with upside tied to clinical adoption, regulatory approvals and execution in a competitive but structurally attractive GI diagnostics market.